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In the period of June 2008-2009 the overall number of licensing deals across all therapeutic areas fell 22% to around 667 from 814 the previous year. This can largely be attributed to the economic shock affecting all industries, and while the number of oncology therapeutic licensing deals has fallen in line with this trend (a drop of 15% from 169 to 143), oncology retained its position as the top therapeutic area for deal making. The continued appetite in this sector reflects the prediction that oncology is set to be a leading revenue growth area over the coming years, with an estimated CAGR of 6% between 2008-2014, compared to 2% for the pharmaceutical industry as a whole.
Highlighting the shortage of late stage development candidates and the intense competition for biological technology platforms, the last 12 months have seen a significant shift towards earlier stage deals. In fact, compared to the previous year, there has been an increase of over 50% in the number of deals for discovery or preclinical programmes, compared to a marked drop in deal numbers for late-stage products for the same time period (Figure 1) . The underlying driver for these changes resides firmly in the credit crunch and equity drought, which has doubled the number of biotech companies with less than a year's cash; consequently many are now facing the necessity of having to partner earlier than the traditional deal making sweet spot of Phase II proof of concept.
The increasing commercial interest and emerging clinical success for high market value biologics and targeted therapies is also reflected in recent deals. When all oncology deal types are considered, the number involving small molecules was notably fewer than those involving biotechnology based products (93 compared to 110), of which deals involving monoclonal antibodies constitute the largest proportion. The majority of antibody based deals are for relatively early stage products but have still commanded high-value deal terms (Table 1) . This appetite for antibodies has been driven by the phenomenal growth and megablockbuster status achieved by MabThera/Rituxan, Avastin and Herceptin. With 2008 sales of US$5.5 B, US$4.8 B and US$4.7B respectively, these antibodies now represent the three top-selling oncology therapeutics world-wide and are within the top 10 of all prescription pharmaceuticals. Given the current pressures on large Pharma from the impending genericisation of these companies' small molecules, the higher hurdles for biogenerics are still providing an additional incentive for existing players to want to expand within this space and to draw relative newcomers to enter this market.
However, that is not to say that small molecules are being forgotten: targeted therapeutics, most notably kinase inhibitors, have also seen a number of large deals in the past year, no doubt encouraged by 2008 sales of US$3.7 B and US$1.6 B for Gleevec and Tarceva respectively, with Sutent and Nexavar also forecast to achieve blockbuster heights in 2010. Exelixis has faired especially well in the tyrosine kinase space with two deals in the last six months: Exelixis has the potential to receive more than US$1 B from each deal ( Table 1) Pharmaceuticals (now a subsidiary of Takeda) announced at BIO 2009 that it plans to make a string of new deals for oncology products and isn't ruling out an acquisition in the US$10 B range. Given this level of stated interest and the high values placed on promising new therapies, oncology deal making looks set to remain a hot topic for the foreseeable future. 
